Skip to main content
Schizophrenia Bulletin logoLink to Schizophrenia Bulletin
. 2020 Jun 7;46(6):1482–1497. doi: 10.1093/schbul/sbaa059

Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test

Rodrigo San-Martin 1, Leonardo Andrade Castro 1, Paulo Rossi Menezes 2,3, Francisco José Fraga 4, Priscyla Waleska Simões 4, Cristiane Salum 1,✉
PMCID: PMC8061122  PMID: 32506125

Abstracts

Prepulse inhibition (PPI) of startle is an operational measure of sensorimotor gating that is often impaired in patients with schizophrenia. Despite the large number of studies, there is considerable variation in PPI outcomes reported. We conducted a systematic review and meta-analysis investigating PPI impairment in patients with schizophrenia compared with healthy control subjects, and examined possible explanations for the variation in results between studies. Major databases were screened for observational studies comparing healthy subjects and patients with schizophrenia for the prepulse and pulse intervals of 60 and 120 ms as primary outcomes, ie, PPI-60 and PPI-120. Standardized mean difference (SMD) and 95% confidence intervals (CI) were extracted and pooled using random effects models. We then estimated the mean effect size of these measures with random effects meta-analyses and evaluated potential PPI heterogeneity moderators, using sensitivity analysis and meta-regressions. Sixty-seven primary studies were identified, with 3685 healthy and 4290 patients with schizophrenia. The schizophrenia group showed reduction in sensorimotor gating for both PPI-60 (SMD = −0.50, 95% CI = [−0.61, −0.39]) and PPI-120 (SMD = −0.44, 95% CI = [−0.54, −0.33]). The sensitivity and meta-regression analysis showed that sample size, gender proportion, imbalance for gender, source of control group, and study continent were sources of heterogeneity (P < .05) for both PPI-60 and PPI-120 outcomes. Our findings confirm a global sensorimotor gating deficit in schizophrenia patients, with overall moderate effect size for PPI-60 and PPI-120. Methodological consistency should decrease the high level of heterogeneity of PPI results between studies.

Keywords: meta-regression, PPI test, sensorimotor gating, systematic review

Introduction

Prepulse inhibition (PPI) of startle is an operational measure of sensorimotor gating that is often impaired in patients with schizophrenia. This phenomenon was demonstrated for the first time in a study with 12 patients with schizophrenia, where a relative loss of prestimulus effects on startle was observed.1 Since then, a great amount of studies have replicated that finding, associating failure of inhibitory filtering mechanism to sensory overload and consequent cognitive fragmentation,2 suggesting reduced PPI as a phenotype of schizophrenia.3 The PPI test evaluates the reduction in startle response to an intense pulse (P) stimulus, closely (30–500 ms) preceded by a weak prepulse (PP).4–7 PPI is not exclusively reduced in schizophrenia, being described in other neuropsychiatric disorders, such as obsessive compulsive disorder (OCD), Tourette syndrome (TS), and Huntington’s disease (HD).8 Therefore, PPI has been considered a preattentive information process, whose failure may predict cognitive deficits.9,10

Patients with schizophrenia also display other forms of sensory gating deficits, which can be evaluated by electroencephalography through auditory elicited event-related potential components, such as P50.11 These deficits have been attributed to a reduction in short-term habituation. In contrast, PPI involves sensory stimuli and motor responses, being therefore a sensorimotor gating and, clearly, not a form of habituation.2

PPI has been considered a cross-species sensorimotor gating paradigm. Animal studies first linked PPI to ventral striatum (nucleus accumbens) and dopamine,9,10 which were subsequently considered central to a descending forebrain circuitry of cortico-striato-pallido-pontine (CSPP) interconnected substrates.4,12 It has been proposed that pedunculopontine nucleus transmits the regulatory “tone” from the forebrain circuit to the primary startle circuitry via descending efferent projections from ventral pallidum, modifying the inhibitory effect of the prepulse stimulus on the startle reflex.4 This circuitry overlaps with regions associated to psychopathological manifestations seen in patients with schizophrenia,3,7,12–14 such as thought disorder,15 deficits in social cognition and emotion perception.16–20 Additionally, brain structural reductions in hippocampus, amygdala, thalamus, and nucleus accumbens21 also intersect with regions associated to the CSPP circuitry. Abnormalities in brain regions that are directly or indirectly involved in PPI regulation might influence the sensorimotor gating in patients with schizophrenia.3,4,22 Thus, PPI has been considered a “pontine portal,” indirectly reflecting higher order neuropathological impairments.7

Although PPI impairment in patients with schizophrenia is considered a consistent finding,23 considerable variation in the magnitude of impairment and sensitivity to moderating variables have been observed between studies. Specifically, numerous studies have revealed that PPI deficits in schizophrenia depend on intrinsic variables used in the test, such as the interval between P and PP (some studies reported deficits for 60 but not for 120 ms,6,14,24 while others reported the opposite12,25; some studies reported deficits for both intervals,26,27 while others neither for 60 or 12028), and on other characteristics of the samples gender,22,29,30 ethnicity,31 age distribution, source of the control group,6,32–34 genetic polymorphisms,35 and use of medications.36–38 We conducted a systematic review to identify studies that compared PPI response between patients with schizophrenia and controls, and a meta-analysis to investigate potential sources of variation in the magnitude of PPI impairment between studies.

Methods and Materials

Search Strategy and Study Selection

The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.39 The study protocol was registered in PROSPERO: CRD42017080864. We searched for articles published before February 27, 2020, identified by searching major electronic bibliographical databases (Embase, PubMed, and the Cochrane). The search was conducted in February 28, 2020 with the following search terms: [Schizophrenias OR “Schizophrenic Disorders” OR “Disorder, Schizophrenic” OR “Disorders, Schizophrenic” OR “Schizophrenic Disorder” OR “Dementia Praecox” OR schizophrenia] AND [“Inhibition, Prepulse” OR “prepulse inhibition”] AND [“human” OR patient OR patients OR humans OR subject OR “clinical trial” OR “clinical trials” OR “randomized controlled trial” OR “placebo” OR “controlled clinical trial”] and synonymous presented in the Medical Subject Heading (MeSH) and in the Embase subject headings (Emtree).

Retrieved articles were screened on the basis of title or abstract reading using the Rayyan web platform for systematic reviews.40 Remaining articles were downloaded and assessed for eligibility through full text reading. Selection procedures were performed independently by 2 researchers (R.S.-M. and L.A.C.) with disagreements on study selection resolved by consensus after discussion.

Studies had to fulfill the following inclusion criteria: (1) observational case–control studies of PPI response comparing a group of patients with schizophrenia or a mixed group of patients with schizophrenia, schizoaffective, or schizophreniform disorder, according to Diagnostic and Statistical Manual of Mental Disorders (DSM)41 or International Statistical Classification of Diseases and Related Health Problems (ICD),42 with a group of healthy subjects (HS); (2) evaluation of PPI with 60 and/or 120 ms intervals (termed PPI-60 and PPI-120, respectively) in both, cases and controls; (3) published in English; and (4) not attention-dependent PPI. Studies were excluded if PPI impairment was not reported as a percentage value or if there was any intervention in one or the 2 groups. In the case of sample overlap, the most recent study was considered for inclusion.

Data Extraction and Processing

The primary outcome of interest was the PPI response. The following study characteristics were registered: title, publication year, authors, country, and continent of the study. In relation to PPI-60 and PPI-120, we extracted the average response for each group, with corresponding standard deviation. We also extracted the sample size, gender distribution, years of education, and mean age of participants for each group. Exclusively for patients with schizophrenia, we collected age of onset, illness duration, Global Assessment of Functioning (GAF), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS) and Positive and Negative Symptoms Scale (PANSS+ and PANSS−) scores, antipsychotic drug category (Nothing, Typical, Atypical, Mixed), diagnosis criteria (DSM or ICD), and group diagnosis description, as some studies included schizoaffective patients in the schizophrenia group. Patients were also characterized by first-psychotic episode, antipsychotic naïve, and benzodiazepines treatment. For the healthy control group, we recorded source (exclusively community-based or mixed with hospital staff, students, or other groups), absence of first-degree relative with psychosis and socioeconomic matching to patients with schizophrenia. Studies were classified as balanced for age if the age difference between the 2 groups was smaller than the sum of standard error of both groups. Also, classified as balanced for gender if the difference in percentage of men in the 2 groups was smaller than 15%. Whenever any article presented more than one case–control investigation, the information was separated as 2 studies.6,30,43 On the other hand, some studies used one healthy control group for comparison with more than one case group, which differed according to antipsychotic medication,34,38,43–48 personality characteristics49 or to other assessment than PPI as the use of different magnetoencephalogram equipment.50 In these cases, groups were merged using adjusted weights according to group sizes to PPI and all other variables.

Quality Assessment and Risk of Bias

The quality of selected studies was evaluated with the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool51 (supplementary table 1), which considers biases from confounding, selection of participants, missing data, and measurement of outcomes. Low bias risk indicates a high-quality study, according to the tool. Two investigators (R.S.-M. and L.A.C.) evaluated each study using the check-list provided by the ROBINS-I tool. The inter-rater agreement percentage was calculated on the overall Risk of Bias and disagreements were resolved by consensus after discussion. Publication bias was assessed with a funnel plot, complemented by the asymmetry analysis, with the Egger test.

Statistical Analysis

Statistical analyses were carried out with the software R 3.4.2 (Comprehensive R Archive Network, http://cran.r-project.org/), using the libraries meta 2.0-0 and metafor 4.9-1. Statistical analyses were conducted separately for PPI-60 and PPI-120 primary outcomes, since inconsistent results have been reported between studies for each one of these intervals.4

Meta-analysis

Meta-analysis was performed to obtain an estimate of the standardized mean difference (SMD) of PPI between patients with schizophrenia and healthy controls, with 95% confidence intervals (95% CI).52,53 A random-effects model was used due to expected high heterogeneity among the PPI studies, as the true effect is influenced by several factors, such as confounding cofactors generated by clinical and demographic differences between subjects.30,31 Hedge’s g was used to compute the effect size, where 0.2 is assumed to be a small effect, 0.5 moderate and 0.8 a large effect.54 τ-squared and Cochrane Q statistic were used to assess probability of heterogeneity for each analysis, and the I2 described the proportion of variability due to heterogeneity, rather than chance.24,55P values were considered statistically significant at the α = 0.05 level.

Sensitivity Analyses

In order to explain the heterogeneity of results between PPI studies and to identify potential associated factors, subgroup analyses were conducted. Moreover, differences between groups were evaluated by random-effects model.52,53 Ethnicity,6,56,57 gender,22,30,58,59 education attainment,60 drug treatment,61,62 and disease severity levels63 have been reported to influence PPI outcome. Similarly, study related variables, such as sample size64 and recent technological advances, may also influence the outcome. Thus, sensitivity analyses were performed for study continent, sample size, gender proportion,65 source of control group, antipsychotic treatment, age or/and gender imbalance and antipsychotic naivety (which coincides with first-psychotic episode for all studies). We were not able to examine other cofactors that might explain PPI heterogeneity due to limitations in the available data, specifically for ethnicity, country, antipsychotic group (atypical, typical, mixed, nothing) or other specific drug, such as benzodiazepines.

Meta-regression

Age is known to influence PPI measures,66 therefore meta-regression52,53 was performed for age of patients with schizophrenia and also for the mean age difference between case and control groups. The same procedure was used for years of education, because education attainment has been associated to symptom severity in patients with schizophrenia.60 Age of onset has shown to be negatively correlated to PPI measures in male patients with schizophrenia,30 and duration of illness influenced schizophrenia P300 in a meta-analytic study.67 Symptom severity is also expected to influence PPI measures,63 hence SANS, SAPS, PANSS+, and PANSS− severity scores were also investigated. In order to explore study-related variables, meta-regression was also performed for sample size and publication year.

Results

Database and Study Characteristics

From 1611 primary articles identified after duplicate removal, 142 were selected for full text review, of which 646,22,25–30,32–34,38,43–50,63,68–110 met all eligibility criteria (figure 1). From these, 3 articles reported 2 experiments with distinct participants each,6,30,43 resulting in 67 studies included. Study characteristics are described in table 1. PPI-60 and PPI-120 results and ROBINS-I are described in table 2. The overall ROBINS-I agreement between the blind evaluators was 82.5%. Europe accounted for 50.8% of the studies, America with 32.8% and the remaining 16.4% came from Asia. The total sample size was 4290 patients and 3685 healthy participants. Male subjects represented 66.0% of all participants. Most studies included both male and female cases and controls, but 17 studies included male subjects only28–30,32,33,44–46,49,50,63,69,75,95,99,101,102 and 2 included only women.22,30 Most recent studies adopted DSM-IV or ICD-10 criteria to define cases. The DSM-III was used in only one study to define schizophrenia.26 Most studies included were observational case–control ones, but 7 recorded baseline PPI before drug or other interventions.27,33,38,44,63,73,87 For these studies, just the baseline data were considered. Data analysis showed asymmetry and evidence of publication bias for both PPI-60 (P < .001) and PPI-120 (P < .001).

Fig. 1.

Fig. 1.

PRISMA flow diagram illustrating the selection of included studies in the meta-analysis.

Table 1.

Characteristics of Studies Included in the Systematic Review and Meta-analysis

Study Continent Subject Number Age (Mean) Education Years (Mean) Diagnosis Ilness Duration (Mean) PANSS Drug Treatment
HC SZ HC SZ HC SZ + −
Braff et al26 America 37 39 33.4 32.4 15.2 11.7 SZ 12.5 Mixed
Braff et al29 America 24 39 27.4 35.7 14.8 11.7 SZ 13.4 Mixed
Kumari et al44 Europe 11 20 37.35 SZ/SZA 13.15 9.6 12 Mixed
Cadenhead et al68 America 25 23 41.1 34.4 15 12.2 SZ Mixed
Kumari et al45 Europe 20 38 36.79 12.81 SZ/SZA 12.81 9.7 12 Mixed
Parwani et al69 America 18 19 44.9 45.5 13.2 11.8 SZ 21.85 26 23 Mixed
Braff et al70 America 30 26 31.6 39.3 15.8 11.8 SZ 16.9 Mixed
Perry et al71 America 17 16 33.5 33.3 15.1 12.2 SZ 8.3 Mixed
Kumari et al46 Europe 20 30 29.5 38.87 SZ/SZA 14.03 8.8 10 Mixed
Ludewig et al72 Europe 44 67 37 39 SZ 13.73 12 14 Mixed
Ludewig et al72 Europe 24 19 30 42 SZ 21 17 22 Mixed
Mackeprang et al73 Europe 20 20 26.1 27.47 SZ 21 20 Nothing
Oranje et al47 Europe 35 44 36.6 34.6 SZ 13.66 17 16 Mixed
Perry et al25 America 13 20 29.6 34.9 15.6 12 SZ Mixed
Ludewig et al75 Europe 24 21 24.6 22.3 SZ 18 17 Nothing
Kumari et al30 Europe 15 27 43.22 SZ 17.42 19 19 Typical
Kumari et al30 Europe 20 15 45.93 SZ 20.07 12 18 Typical
Perry et al77 America 13 14 29.7 36.4 15.6 11.6 SZ 19 Mixed
Wynn et al76 America 41 76 33.64 42.7 SZ Mixed
Braff et al22 America 26 25 38.1 12.7 SZ 14.4
Kumari et al43 Europe 14 23 35.36 34.57 SZ 11 19 Mixed
Kumari et al43 Europe 14 39 33.71 36.97 SZ 9.3 11 Mixed
Kumari et al43 Europe 22 35 32.82 43.91 SZ 16 18 Mixed
Quednow et al108 Europe 18 28 39.6 38.34 13.9 13.87 SZ 9.5 23 23 Atypical
Swerdlow et al78 America 66 103 33.54 43.98 15.12 12.28 SZ 20.42 Mixed
Braff et al80 America 81 110 34.41 43.37 14.81 12.16 SZ
Heresco et al83 Asia 30 30 36.8 40.5 14.9 10.4 SZ 23 29 Mixed
Hong et al84 America 17 59 39.8 40.8 SZ Mixed
Kumari et al81 Europe 20 20 27.3 24.55 SZ 21 20 Nothing
Kunugi et al82 Asia 16 20 41 42 SZ 13 22
Minassian et al79 America 20 23 31.9 35.3 SZ Mixed
Hong et al87 America 63 113 37.1 39.1 14.1 12.8 SZ Mixed
Kumari et al86 Europe 22 62 35.23 38.78 15.18 13.59 SZ/SZA 15.12 17 18 Mixed
Takahashi et al85 Asia 55 51 40.4 38.1 14.7 14.1 SZ 14.4 18 19 Mixed
Csomor et al88 Europe 43 13 27.3 24.3 SZ 13 14 Nothing
Martinez et al63 Europe 36 45 36.53 36.5 15.5 18.94 SZ 12 15 Typical
Moriwaki et al89 Asia 107 100 32.7 51.6 SZ 26.71 Mixed
Woznica et al109 America 10 15 35 41.5 16 13.3 SZ 16 15 Atypical
Aggernaes et al90 Europe 31 31 26 25.3 SZ 20 23 Nothing
Hasenkamp et al92 America 100 40 SZ 18 15 Atypical
Molina et al91 Europe 16 23 29.4 37.5 13.7 10.7 SZ 10.1 28 24 Nothing
Hammer et al93 Europe 17 13 28.6 30 SZ 20 21 Nothing
Hasenkamp et al94 America 94 107 37.6 43.2 SZ 18 15 Mixed
Molina et al27 Europe 16 21 29.4 40.5 13.7 10.7 SZ 8.1 28 24 Nothing
Preuss et al48 Europe 26 36 29.92 32.66 SZ 11.76 15 17 Mixed
Light et al96 America 205 341 44.39 11.91 SZ 22.72 Mixed
Storozheva et al28 Europe 16 9 SZ
Wang et al95 Asia 22 41 SZ Mixed
Xue et al34 Asia 31 26 26.29 24.5 14.61 13.11 SZ 25 19 Nothing
Hammer et al50 Europe 38 27 27.17 27.17 SZ 20 22 Nothing
Kishi and Iwata97 Asia 107 100 32.7 50.8 15.1 11.3 SZ 25.6 18 21 Mixed
Wang et al105 Asia 30 31 22.1 20.4 8.5 8.5 SZ 16 20 Nothing
Düring et al106 Europe 47 52 25.8 24.9 SZ 20 21 Nothing
Ivleva et al98 America 53 64 36.84 40.58 13.7 13.66 SZ Mixed
Morales-Muñoz et al99 Europe 44 54 26.59 25.3 15.73 16.79 SZ 11 14 Atypical
Bertelsen et al100 Europe 106 49 26.7 25.4 SZ 20 24 Nothing
Rubio et al33 Europe 28 58 36.6 36.3 18.4 17.9 SZ 17 20 Typical
Matsuo et al103 Asia 250 181 36.7 37.6 15.5 13.9 SZ 14.1 15 16 Mixed
Mena et al104 Europe 13 26 36.77 37.31 SZ 17 16 Mixed
Morales-Muñoz et al110 Europe 38 38 30.3 26.7 11.58 10.92 SZ 19 16 Atypical
Shi et al101 Asia 62 77 40.81 44.69 10.12 8.84 SZ 22.49 12 18 Mixed
Storozheva et al102 Europe 25 28 26.4 35.3 SZ Nothing
Fargotstein et al38 America 108 132 36.9 42.7 SZ 17 15 Mixed
Morales-Muñoz et al32 Europe 50 54 26.92 22.89 SZ
Swerdlow et al6 America 304 317 38.83 46.03 14.98 12.42 SZ/SZA 23.67 Mixed
Swerdlow et al6 America 628 771 38.45 46.24 15.02 12.77 SZ/SZA 23.87 Mixed
Li et al107 Asia 49 56 26.21 25.9 14.12 13.18 SZ 23 19 Atypical

Note: Empty fields are information not reported in the study. PANSS, Positive and Negative Symptoms Scale; SZ, patients with schizophrenia; SZA, schizoaffective patients; Mixed, patients treated with typical and/or atypical patients; Nothing, patients naïve or absent for more than 1 month of antipsychotic treatment.

Table 2.

PPI Means and Risk of Bias in Nonrandomized Studies (ROBINS-I) for Studies Included in the Systematic Review and Meta-analysis

Study PPI-60 (Mean ± SD) PPI-120 (Mean ± SD) Risk of Bias
HC SZ HC SZ ROBINS-I
Braff et al26 55 ± 59 31 ± 38 70 ± 54 47 ± 40 Low
Braff et al29 66 ± 34 45 ± 36 Low
Kumari et al44 50 ± 13 28 ± 27 58 ± 10 36 ± 21 Moderate
Cadenhead et al68 63 ± 25 64 ± 25 Low
Kumari et al45 47 ± 21 33 ± 33 60 ± 18 53 ± 30 Moderate
Parwani et al69 65 ± 30 43 ± 37 88 ± 8 57 ± 24 Low
Braff et al70 63 ± 20 46 ± 25 Moderate
Perry et al71 66 ± 25 54 ± 25 75 ± 25 64 ± 25 Low
Kumari et al46 47 ± 20 32 ± 39 60 ± 19 56 ± 29 Moderate
Ludewig et al74 62 ± 23 49 ± 29 57 ± 25 52 ± 35 Moderate
Ludewig et al72 64 ± 25 39 ± 25 57 ± 25 47 ± 25 Low
Mackeprang et al73 73 ± 28 48 ± 26 83 ± 16 65 ± 31 Moderate
Oranje et al47 62 ± 16 50 ± 34 Moderate
Perry et al25 67 ± 25 48 ± 25 75 ± 25 59 ± 25 Moderate
Ludewig et al75 68 ± 15 55 ± 20 58 ± 24 54 ± 30 Low
Kumari et al30 36 ± 20 14 ± 22 47 ± 17 22 ± 23 Moderate
Kumari et al30 25 ± 21 28 ± 15 33 ± 16 38 ± 23 Moderate
Perry et al117 66 ± 16 31 ± 24 79 ± 12 42 ± 20 Moderate
Wynn et al76 52 ± 30 59 ± 33 Moderate
Braff et al22 67 ± 32 47 ± 42 Moderate
Kumari et al49 42 ± 23 25 ± 33 58 ± 16 44 ± 37 Low
Kumari et al43 53 ± 3 55 ± 6 58 ± 6 59 ± 9 Moderate
Kumari et al43 50 ± 20 33 ± 25 64 ± 17 54 ± 24 Moderate
Quednow et al108 55 ± 14 40 ± 27 Moderate
Swerdlow et al78 48 ± 24 38 ± 32 57 ± 17 60 ± 23 Moderate
Braff et al80 53 ± 29 40 ± 34 64 ± 26 61 ± 25 Low
Heresco et al83 42 ± 31 30 ± 29 50 ± 23 39 ± 37 Moderate
Hong et al84 29 ± 25 24 ± 25 55 ± 25 35 ± 25 Moderate
Kumari et al81 48 ± 25 33 ± 36 65 ± 25 41 ± 35 Moderate
Kunugi et al82 12 ± 72 29 ± 34 57 ± 26 33 ± 28 Moderate
Minassian et al79 64 ± 19 47 ± 25 70 ± 23 66 ± 24 Moderate
Hong et al87 49 ± 16 41 ± 25 Moderate
Kumari et al86 31 ± 22 17 ± 33 46 ± 23 28 ± 34 Low
Takahashi et al85 50 ± 17 32 ± 41 Moderate
Csomor et al88 58 ± 23 41 ± 24 57 ± 27 57 ± 27 Low
Martinez et al63 37 ± 15 7 ± 10 38 ± 11 18 ± 12 Low
Moriwaki et al89 44 ± 26 32 ± 32 Moderate
Woznica et al109 38 ± 25 25 ± 25 47 ± 25 19 ± 25 Low
Aggernaes et al90 50 ± 37 56 ± 35 62 ± 35 59 ± 47 Low
Hasenkamp et al92 43 ± 58 50 ± 32 42 ± 75 59 ± 34 Low
Molina et al91 57 ± 27 46 ± 29 Moderate
Hammer et al93 62 ± 35 32 ± 73 61 ± 47 45 ± 78 Moderate
Hasenkamp et al94 44 ± 62 40 ± 62 57 ± 59 58 ± 43 Moderate
Molina et al27 63 ± 29 42 ± 28 Moderate
Preuss et al48 73 ± 21 65 ± 22 75 ± 15 60 ± 33 Moderate
Light et al96 52 ± 34 47 ± 25 66 ± 22 63 ± 25 Moderate
Storozheva et al28 52 ± 9 34 ± 13 40 ± 13 33 ± 22 Moderate
Wang et al95 29 ± 18 16 ± 29 42 ± 21 22 ± 34 Moderate
Xue et al34 65 ± 25 43 ± 25 56 ± 25 42 ± 25 Moderate
Hammer et al50 73 ± 5 61 ± 7 Moderate
Kishi and Iwata97 44 ± 26 32 ± 32 Moderate
Wang et al105 23 ± 23 8 ± 26 36 ± 42 35 ± 29 Low
Düring et al106 60 ± 35 51 ± 33 60 ± 41 48 ± 43 Low
Ivleva et al98 50 ± 21 44 ± 34 Moderate
Morales-Muñoz et al99 27 ± 63 14 ± 30 47 ± 44 27 ± 36 Moderate
Bertelsen et al100 55 ± 32 53 ± 29 57 ± 33 56 ± 32 Low
Rubio et al33 30 ± 8 15 ± 5 43 ± 10 24 ± 8 Moderate
Matsuo et al103 39 ± 25 30 ± 25 67 ± 25 56 ± 25 Moderate
Mena et al104 45 ± 18 18 ± 33 Low
Morales-Muñoz et al110 23 ± 25 5 ± 25 32 ± 25 20 ± 25 Moderate
Shi et al101 19 ± 34 18 ± 25 46 ± 20 35 ± 21 Moderate
Storozheva et al102 67 ± 26 48 ± 31 65 ± 29 46 ± 32 Low
Fargotstein et al38 47 ± 49 48 ± 44 52 ± 41 55 ± 36 Low
Morales-Muñoz et al32 25 ± 22 14 ± 15 47 ± 15 27 ± 18 Low
Swerdlow et al6 43 ± 40 34 ± 68 55 ± 32 51 ± 43 Low
Swerdlow et al6 45 ± 42 37 ± 47 57 ± 37 53 ± 47 Low
Li et al107 28 ± 19 20 ± 20 28 ± 20 20 ± 26 Low

Note: Empty fields indicated that the PPI was not evaluated for the interval in the study. PPI are represented as the mean ± standard deviation (SD) or median ± data imputed SD. ROBINS-I, Risk of Bias In Non-randomized Studies of Interventions tool.

Overall PPI-60 and PPI-120

Figure 2 shows the forest plot for PPI-60 and PPI-120 SMDs with 95% confidence intervals and a summary mean difference showing average reductions of PPI-60 (SMD = −0.50, 95% CI = [−0.61, −0.39], P < .0001) and PPI-120 (SMD = −0.44, 95% CI = [−0.54, −0.33], P < .0001) in patients with schizophrenia when compared with healthy controls. The heterogeneity across studies was substantial for both PPI-60 (I2 = 74%, 95% CI = [66%, 80%]) and PPI-120 (I2 = 77%, 95% CI [70%, 82%]).

Fig. 2.

Fig. 2.

Studies of PPI-60 and PPI-120 in individuals with schizophrenia compared with healthy subjects. Standardized mean difference forest plots for PPI-60 and PPI-120.

Sensitivity Analysis

Subgroup analyses were conducted using stratification by study continent, sample size, gender proportion, imbalance for gender and age, source of control group, antipsychotic treatment, and antipsychotic naïve. Figure 3 shows the forest plots with PPI-60 and PPI-120 SMDs and 95% confidence intervals according to stratum. There was no evidence of effect modification by antipsychotic treatment, including treatment vs antipsychotic naïve patients, for both PPI-60 and PPI-120. On the other hand, balanced groups for age showed greater impairment in patients with schizophrenia for PPI-120 (SMD = −0.63, 95% CI = [−0.83, −0.42], I2 = 79%) than imbalanced ones (SMD = −0.32, 95% CI = [−0.44, −0.20], I2 = 68, P = .0121). European studies (PPI-60: SMD = −0.65, 95% CI = [−0.85, −0.45], I2 = 77%; PPI-120: SMD = −0.54, 95% CI = [−0.74, −0.34], I2 = 78%) showed larger deficits in patients with schizophrenia when compared with American (PPI-60 SMD = −0.29, 95% CI = [−0.41, −0.16], I2 = 55%; PPI-120 SMD = −0.24, 95% CI [−0.38, −0.10], I2 = 71%) and Asian studies (PPI-60: SMD = −0.35, 95% CI [−0.54, −0.16], I2 = 39%, P = .0106; PPI-120: SMD = −0.44, 95% CI [−0.55, −0.34], I2 = 0%, P = .0238), with the latter exhibiting reduced PPI heterogeneity when compared with American and European studies. Studies balanced for gender (PPI-60: SMD = −0.59, 95% CI = [−0.76, −0.43], I2 = 75%; PPI-120: SMD = −0.58, 95% CI = [−0.73, −0.44], I2 = 73%) also presented larger deficits in patients with schizophrenia than imbalanced studies (PPI-60: SMD = −0.29, 95% CI = [−0.42, −0.16], I2 = 54%, P = 0.0046; PPI-120: SMD = −0.13, 95% CI [−0.24, −0.02], I2 = 46%, P ≤ .0001). Studies with 90% or more male participants found larger PPI impairment in patients with schizophrenia (PPI-60: SMD = −0.78, 95% CI = [−1.11, −0.44], I2 = 84%; PPI-120: SMD = −0.85, 95% CI = [−1.17, −0.54], I2 = 82%) than studies with less than 90% male participants (PPI-60: SMD = −0.36, 95% CI [−0.45, −0.27], I2 = 52%, P = .0183; PPI-120: SMD = −0.27, 95% CI [−0.36, −0.19], I2 = 55%, P = .0005). Moreover, studies with subject balance for both age and gender detected higher deficits for PPI-120 (SMD = −0.68, 95% CI = [−0.91, −0.44], I2 = 81.6%) than imbalanced ones (SMD = −0.32, 95% CI = [−0.45, −0.21], I2 = 65.6%, P = .0097). Studies with 100% community-based controls found smaller effect sizes and reduced PPI heterogeneity (PPI-60: SMD = −0.32, 95% CI = [−0.42, −0.22], I2 = 38%; PPI-120: SMD = −0.31, 95% CI = [−0.42, −0.20], I2 = 64%) than mixed control groups (PPI-60: SMD = −1.09, 95% CI = [−1.58, −0.60], I2 = 86%, P = .0026; PPI-120: SMD = −0.86, 95% CI = [−1.35, −0.38], I2 = 86%, P = .0284). Studies with more than 100 subjects also found smaller PPI reduction (PPI-60: SMD = −0.21, 95% CI = [−0.30, −0.12], I2 = 41%; PPI-120: SMD = −0.21, 95% CI = [−0.32, −0.09], I2 = 73%) than studies with 100 or less subjects (PPI-60: SMD = −0.65, 95% CI [−0.82, −0.48], I2 = 69%, P <.0001; PPI-120: SMD = −0.60, 95% CI = [−0.75, −0.44], I2 = 69%, P < .0001). The multi-site study Consortium on the Genetics of Schizophrenia (COGS) study6 did not influence the outcome for studies with more than 100 subjects but influenced continent group comparison in PPI-120. These results are reported in supplementary materials.

Fig. 3.

Fig. 3.

Sensitivity analyses of PPI in patients with schizophrenia. Group diff P value indicates the subgroups differences comparison under the random effects model.

Meta-regression

In order to evaluate if PPI heterogeneity could be explained by some continuous variables, a meta-regression was performed. Variables included in the meta-regression were patients’ age and education, differences in age and education between cases and controls, age of onset of schizophrenia, duration of illness, SAPS, SANS, PANSS+, PANSS− scores, sample size, and study publication year (table 3). There was no evidence of effect modification for PPI-60 and PPI-120 according to patients’ age, age difference between cases and controls, age of onset of schizophrenia, SAPS, SANS, PANSS+ and PANSS− scores, and year of publication. SMD effect size reduced as patients’ education years increased (PPI-60: P < .0001, β = −0.1391, R2 = 23%; PPI-120: P = .0002, β = −0.1183, R2 = 21%). SMD effect size reduced, as education years difference between cases and controls increased (PPI-60: P = .0096, β = −0.1335, R2 = 17%; PPI-120: P = .0242, β = −0.1028, R2 = 21%), indicating that with higher educational difference, smaller PPI deficits were observed in patients with schizophrenia when compared with healthy subjects. Figure 4 shows meta-regression effects of PPI-60 and PPI-120 by patients’ education years and education years difference between cases and controls. Duration of illness was significant for PPI-60 only, with its increase being related to higher SMD effect size for PPI-60 in patients with schizophrenia (PPI-60: P = .0001, β = 0.0285, R2 = 100%).

Table 3.

Meta-regression Moderators of PPI in Patients With schizophrenia

PPI-60 PPI-120
Variables Sample β P R  2 (%) Sample β P R  2 (%)
Age of SZ 52 0.0094 .1910 9 60 0.0080 .2348 9
Age difference 47 0.0102 .2837 7 54 0.0060 .5128 6
Education of SZ 26 −0.1391 <.0001 23 31 −0.1183 .0002 21
Education dif. (SZ-CT) 24 −0.1335 .0096 17 28 −0.1028 .0242 21
SZ onset 29 0.0499 .2415 0 31 0.0237 .5051 0
Duration of illness 21 0.0285 .0001 100 25 0.0168 .1079 25
SAPS 8 −0.0170 .1046 59 7 −0.0175 .0887 100
SANS 11 −0.0112 .2653 21 10 −0.0212 .0797 23
PANSS + 39 −0.0091 .6279 0 43 −0.0169 .3387 0
PANSS − 38 0.0002 .9935 0 42 −0.0242 .2208 1
Sample size 55 0.0005 .0327 0 63 0.0005 .0298 0
Publication year 55 0.0114 .2044 8 63 0.0016 .8681 0

Note: SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; PANSS+ and PANSS−, Positive and Negative Symptoms Scale; Sample, total number or studies examining the moderator. Education difference: difference between years of study for patients with schizophrenia and healthy subjects. Statistical significance at .05 level (2-tailed). In bold, comparisons with P < .05.

Fig. 4.

Fig. 4.

Meta-regression analyses. Effect of PPI-60 and PPI-120 (SMD) by SZ education (A) and education years difference (B) between healthy subjects and patients with schizophrenia.

Discussion

To the best of our knowledge, this is the first systematic review with meta-analysis to examine PPI deficits in patients with schizophrenia compared with healthy controls, exploring sources of PPI heterogeneity among studies’ results. Individuals with schizophrenia showed reduced sensorimotor gating with moderate effect size for both PPI-60 (SMD = −0.50) and PPI-120 (SMD = −0.44). Substantial heterogeneity was observed across studies. Sensitivity analysis and meta-regression showed that the heterogeneity could be partly explained by study continent, sample size, gender proportion, imbalance for gender, source of controls, patient’s educational level, and educational difference between cases and controls.

PPI as a Global Sensorimotor Gating Deficits Index in Patients With Schizophrenia

PPI impairment in patients with schizophrenia was expected, since sensorimotor gating mechanisms are regulated by a complex circuitry involving descending forebrain pathways,7 and the pathophysiology of schizophrenia also involves impairments in several brain regions that participate in the PPI regulatory circuitry.111 Our meta-analytic synthesis revealed a moderate effect size for this test, with results from most studies showing some impairment in patients with schizophrenia, when compared with healthy controls. PPI impairment appears to be a global schizophrenia-related phenotype, consequent of disturbances within forebrain circuitry of relevance to many neurodevelopmental disorders.3 A recent cognitive, neurophysiological, and computational model for schizophrenia112 proposes complex interactions in psychotic illnesses, involving low-level information processing in sensory cortices and information processing in higher levels of the predictive coding hierarchy. Our results reinforce the hypothesis of disturbances of these low- and high-level circuitries.

Sources of Heterogeneity in PPI Impairment

The high PPI heterogeneity observed seems to largely reflect differences related to methodological aspects of studies, as shown by the results from sensitivity and meta-regression analyses. Gender proportion among cases and controls and gender imbalance between case and control groups partly explained the observed heterogeneity. Considerable evidence point to sexual dimorphisms in patients with schizophrenia, such as increased size of ventricles and smaller frontal lobe in men than in women (for a comprehensive review, see Mendrek and Mancini-Marïe58). Moreover, other alterations akin to the normal sexual dimorphism are observed in this pathology, as brain asymmetry and cognitive functions regulated by corticolimbic structures. Some PPI investigations were performed exclusively with male patients, while studies with female patients are scarce. PPI impairment in female patients with schizophrenia compared with healthy women have shown inconsistent results.22,30 Factors that may have influenced results include differences in data processing or stimuli presentation22 and the menstrual status of participants,36,113 and a floor effect size, as healthy woman show reduced PPI when compared with men.59 The small number of studies investigating exclusively female participants limited the evaluation of the association of gender with PPI heterogeneity. Therefore, we compared predominantly studies with very high proportions of men (>90%) with those with smaller proportions, and found larger effect size in the former group (PPI-60: SMD = −0.78; PPI-120: SMD = −0.85), as compared with the remaining studies (PPI-60: SMD = −0.36; PPI-120: SMD = −0.27). Additionally, groups balanced for gender (PPI-60: SMD = −0.59; PPI-120: SMD = −0.58) also yielded larger effect size than imbalanced groups (PPI-60: SMD = −0.29; PPI-120: SMD = −0.13). Summarizing, there is a need for gender matching between groups and more data for female patients and controls, regarding PPI impairment.

This meta-analysis also showed that sources of controls and differences in educational attainment114 between patients and controls contributed to the observed PPI heterogeneity. Studies that mixed community controls with hospital staff or other sources found greater PPI impairment (PPI-60: SMD = −1.09; PPI-120: SMD = −0.86), when compared with studies that recruited community controls exclusively (PPI-60: SMD = −0.32; PPI-120: SMD = −0.31). Likewise, greater PPI effect size was also observed when there was a higher educational attainment difference between cases and controls (PPI-60: β = −0.1391; PPI-120: β = −0.1183). These findings reinforce the need to either use a case–control matching or take into account such potential confounding in the analysis of data.

PPI heterogeneity was also partly explained by study continent. Some studies have described ethnicity effects on PPI,6,56,57 and ethnic differences between continents may be behind the observed association. European studies showed larger heterogeneity and effect sizes (PPI-60: SMD = −0.65 PPI-120: SMD = −0.54), while Asian studies (PPI-60: SMD = −0.35; PPI-120: SMD = −0.44) had lower heterogeneity and were closer to the overall effect size, and American studies found low to moderate effect sizes (PPI-60: SMD = −0.29; PPI-120: SMD = −0.24). These results suggest that ethnicity may have discrete relationship with PPI outcome, and might explain the reduced effect size observed in some American studies that included African-, Asian- and European-American populations (figure 3).

Disease severity scores and antipsychotic treatment were not associated to the PPI heterogeneity observed in the present meta-analysis. The association of PPI with positive29,34,105,115 and negative symptoms,29,34 and with cognitive deficits116–118 have been inconsistent. A large cohort study of patients with schizophrenia has found no association between PPI impairment and positive or negative symptoms.31,78 In that study, PPI impairment was blunted when antipsychotic-medicated patients were compared with antipsychotic-free patients, but the difference between first-generation and second-generation antipsychotics was dependent on minimal startle response exclusion criteria, which led to a loss of almost 40% of the sample.3 In other studies, PPI impairment was either stable over a 1-year interval independently of treatment, or the effect of medication was not observed or was no longer present when the severity of positive symptoms was used as a covariate in the statistical analyses.96,103,115,118 The lack of association between use of antipsychotics and the observed PPI heterogeneity may also be due to the fact that the treated group combined several antipsychotics with different pharmacological mechanisms.119

Publication Bias

The funnel plots (supplementary information) indicated moderate risk of publication bias. In several investigations,4,22,27,47,50,68,76,85,87,89,91,97,98,104,108 only results for one of these intervals were published. It is not possible to know whether that was related to experimental setup issues (for instance, reduction in test duration to decrease patients’ stress) or publication bias due to lack of association for one of these intervals.

Limitations

The present study has some limitations. Benzodiazepine treatment may influence PPI impairment,120 but its use was not reported in most studies and we therefore could not control for its effects in our analyses. Nicotine use is also associated to PPI alterations,109 but we could not control this variable either. We could not analyze the specific effects of typical vs atypical antipsychotic treatment influences, due to the low number of patients under typical treatment. Studies in America were performed only in United States and Canada, Asian studies only in Japan and China, with European studies showing a wider distribution. This points to the lack of investigations in Latin America, other Asian and in African countries. Some authors, such as Ioanidis,121 have made critical reflections on the massive production of systematic reviews in recent years, leading to redundant, conflicting, or misleading conclusions. Our systematic review and meta-analysis sought to identify and fill a knowledge gap related to PPI, using the best current guidelines for conducting a systematic review and meta-analysis of observational studies. PPI study protocols and parameters can have a large variation, including background noise, P and PP characteristics (duration, magnitude, latency), external sound stimulation or headphones, instruction to pay attention or not to auditory stimuli,122 EMG equipment,123 number of trials,124 and stimuli presentation order. These variations may also be related to PPI heterogeneity, but examining such aspects was out of scope of this study, though these aspects influence on PPI should be investigated elsewhere in large studies.

Conclusion

In conclusion, the present systematic review and meta-analysis showed that patients with schizophrenia have an impairment in PPI response compared with healthy controls, with a moderate effect size, indicating that PPI is a global sensorimotor gating deficits index for patients with schizophrenia. Moreover, PPI heterogeneity analyzes showed that methodological aspects, including case–control imbalance for gender, source of control group, and educational attainment differences between groups must be taken into account. We also unveiled a lack of studies with female patients and controls. The synthesis of PPI studies provided in the present study, along with the information on the effect size and moderators that account for heterogeneity of results can be used as guidance for designing future studies.

Supplementary Material

sbaa059_suppl_Supplementary_Material

Acknowledgments

The authors wish to thank Ana Helena Mouffron and Viviane Neri Reis for their valuable insights on the manuscript structure. The authors have declared that there are no conflicts of interest in relation to the subject of this study.

Funding

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001 and São Paulo Research Foundation (FAPESP)—grant #2015/09510-7. PRM is partly funded by CNPq-Brazil. RSM and LC gratefully acknowledge UFABC and CAPES scholarships.

References

  • 1. Braff  D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 1978;15(4):339–343. [DOI] [PubMed] [Google Scholar]
  • 2. Geyer  MA. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci. 2006;8(1):9–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Swerdlow  NR, Light GA. Sensorimotor gating deficits in schizophrenia: advancing our understanding of the phenotype, its neural circuitry and genetic substrates. Schizophr Res. 2018;198:1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Braff  DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156(2–3):234–258. [DOI] [PubMed] [Google Scholar]
  • 5. Geyer  MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001;156(2–3):117–154. [DOI] [PubMed] [Google Scholar]
  • 6. Swerdlow  NR, Light GA, Thomas ML, et al.  Deficient prepulse inhibition in schizophrenia in a multi-site cohort: internal replication and extension. Schizophr Res. 2018;198:6–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Swerdlow  NR, Braff DL, Geyer MA. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016;30(11):1072–1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Swerdlow  NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1995;58(2):192–200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Swerdlow  NR, Braff DL, Geyer MA, Koob GF. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry. 1986;21(1):23–33. [DOI] [PubMed] [Google Scholar]
  • 10. Wan  FJ, Swerdlow NR. Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res. 1996;722(1–2):168–176. [DOI] [PubMed] [Google Scholar]
  • 11. Earls  HA, Curran T, Mittal V. A meta-analytic review of auditory event-related potential components as endophenotypes for schizophrenia: perspectives from first-degree relatives. Schizophr Bull. 2016;42(6):1504–1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Swerdlow  NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl). 2001;156(2–3):194–215. [DOI] [PubMed] [Google Scholar]
  • 13. Fendt  M, Li L, Yeomans JS. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology (Berl). 2001;156(2–3):216–224. [DOI] [PubMed] [Google Scholar]
  • 14. Koch  M. The neurobiology of startlSensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes nexte. Prog Neurobiol. 1999;59(2):107–128. [DOI] [PubMed] [Google Scholar]
  • 15. de Sousa  P, Sellwood W, Griffiths M, Bentall RP. Disorganisation, thought disorder and socio-cognitive functioning in schizophrenia spectrum disorders. Br J Psychiatry. 2018:1–10. [DOI] [PubMed] [Google Scholar]
  • 16. Irani  F, Seligman S, Kamath V, Kohler C, Gur RC. A meta-analysis of emotion perception and functional outcomes in schizophrenia. Schizophr Res. 2012;137(1–3):203–211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Green  MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry. 2012;69(12):1216–1224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Chan  RC, Li H, Cheung EF, Gong QY. Impaired facial emotion perception in schizophrenia: a meta-analysis. Psychiatry Res. 2010;178(2):381–390. [DOI] [PubMed] [Google Scholar]
  • 19. Köther  U, Veckenstedt R, Vitzthum F, et al.  “Don’t give me that look”—overconfidence in false mental state perception in schizophrenia. Psychiatry Res. 2012;196(1):1–8. [DOI] [PubMed] [Google Scholar]
  • 20. Brunet-Gouet  E, Decety J. Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res. 2006;148(2–3):75–92. [DOI] [PubMed] [Google Scholar]
  • 21. Van Erp  TGM, Hibar DP, Rasmussen JM, et al.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21(4):547–553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Braff  DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005;57(7):817–820. [DOI] [PubMed] [Google Scholar]
  • 23. Kohl  S, Heekeren K, Klosterkötter J, Kuhn J. Prepulse inhibition in psychiatric disorders—apart from schizophrenia. J Psychiatr Res. 2013;47(4):445–452. [DOI] [PubMed] [Google Scholar]
  • 24. Huedo-Medina  TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206. [DOI] [PubMed] [Google Scholar]
  • 25. Perry  W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002;159(8):1375–1381. [DOI] [PubMed] [Google Scholar]
  • 26. Braff  DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 1992;49(3):206–215. [DOI] [PubMed] [Google Scholar]
  • 27. Molina  V, López DE, Villa R, et al.  Prepulse inhibition of the startle reflex in schizophrenia remains stable with short-term quetiapine. Eur Psychiatry. 2011;26(5):271–275. [DOI] [PubMed] [Google Scholar]
  • 28. Storozheva  ZI, Kirenskaya AV, Lazarev IE, Novototskii-Vlasov VY, Samylkin DV, Fastovtsov GA. Prepulse modification of the acoustic startle reaction in healthy subjects and patients with schizophrenia. Neurosci Behav Physiol. 2012;42(2):128–132. [PubMed] [Google Scholar]
  • 29. Braff  DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999;156(4):596–602. [DOI] [PubMed] [Google Scholar]
  • 30. Kumari  V, Aasen I, Sharma T. Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res. 2004;69(2–3):219–235. [DOI] [PubMed] [Google Scholar]
  • 31. Swerdlow  NR, Light GA, Sprock J, et al.  Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014;152(2–3):503–512. doi: 10.1016/j.schres.2013.12.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Morales-Muñoz  I, Martínez-Gras I, Ponce G, et al.  Psychological symptomatology and impaired prepulse inhibition of the startle reflex are associated with cannabis-induced psychosis. J Psychopharmacol. 2017;31(8):1035–1045. [DOI] [PubMed] [Google Scholar]
  • 33. Rubio  G, López-Muñoz F, Jurado-Barba R, et al.  Stress induced by the socially evaluated cold-pressor test cause equivalent deficiencies of sensory gating in male subjects with schizophrenia and healthy controls. Psychiatry Res. 2015;228(3):283–288. [DOI] [PubMed] [Google Scholar]
  • 34. Xue  YY, Wang HN, Xue F, Tan QR. Atypical antipsychotics do not reverse prepulse inhibition deficits in acutely psychotic schizophrenia. J Int Med Res. 2012;40(4):1467–1475. [DOI] [PubMed] [Google Scholar]
  • 35. Quednow  BB, Ejebe K, Wagner M, et al.  Meta-analysis on the association between genetic polymorphisms and prepulse inhibition of the acoustic startle response. Schizophr Res. 2018;198:52–59. [DOI] [PubMed] [Google Scholar]
  • 36. Duncan  EJ, Bollini AM, Lewison B, et al.  Medication status affects the relationship of symptoms to prepulse inhibition of acoustic startle in schizophrenia. Psychiatry Res. 2006;145(2–3):137–145. [DOI] [PubMed] [Google Scholar]
  • 37. Leumann  L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry. 2002;52(7):729–739. [DOI] [PubMed] [Google Scholar]
  • 38. Fargotstein  M, Hasenkamp W, Gross R, et al.  The effect of antipsychotic medications on acoustic startle latency in schizophrenia. Schizophr Res. 2018;198:28–35. [DOI] [PubMed] [Google Scholar]
  • 39. Liberati  A, Altman DG, Tetzlaff J, et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Ouzzani  M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Washington, DC: American Psychiatric Pub; 2013. [Google Scholar]
  • 42. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Vol 1. Geneva: World Health Organization; 2004. [Google Scholar]
  • 43. Kumari  V, Ettinger U, Crawford TJ, Zachariah E, Sharma T. Lack of association between prepulse inhibition and antisaccadic deficits in chronic schizophrenia: implications for identification of schizophrenia endophenotypes. J Psychiatr Res. 2005;39(3):227–240. [DOI] [PubMed] [Google Scholar]
  • 44. Kumari  V, Soni W, Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 1999;156(7):1046–1051. [DOI] [PubMed] [Google Scholar]
  • 45. Kumari  V, Soni W, Mathew VM, Sharma T. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiatry. 2000;57(6):609–614. [DOI] [PubMed] [Google Scholar]
  • 46. Kumari  V, Soni W, Sharma T. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res. 2002;55(1–2):139–146. doi: 10.1016/S0920-9964(01)00276-6 [DOI] [PubMed] [Google Scholar]
  • 47. Oranje  B, Van Oel CJ, Gispen-De Wied CC, Verbaten MN, Kahn RS. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol. 2002;22(4):359–365. [DOI] [PubMed] [Google Scholar]
  • 48. Preuss  UW, Zimmermann J, Watzke S, et al.  Short-term prospective comparison of prepulse inhibition between schizophrenic patients and healthy controls. Pharmacopsychiatry. 2011;44(3):102–108. [DOI] [PubMed] [Google Scholar]
  • 49. Kumari  V, Das M, Hodgins S, et al.  Association between violent behaviour and impaired prepulse inhibition of the startle response in antisocial personality disorder and schizophrenia. Behav Brain Res. 2005;158(1):159–166. [DOI] [PubMed] [Google Scholar]
  • 50. Hammer  TB, Oranje B, Skimminge A, et al.  Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia. J Psychiatry Neurosci. 2013;38(1):34–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Sterne  JA, Hernán MA, Reeves BC, et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Borenstein  M, Hedges LV, Higgins JPT, Rothstein HR.  Introduction to Meta-Analysis. West Sussex, UK: John Wiley & Sons; 2011. [Google Scholar]
  • 53. Egger  M, Davey-Smith G, Altman D.  Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group; 2008. [Google Scholar]
  • 54. Cohen  J.  Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Inc.; 1988. [Google Scholar]
  • 55. Higgins  JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Hasenkamp  W, Norrholm SD, Green A, et al.  Differences in startle reflex and prepulse inhibition in European-Americans and African-Americans. Psychophysiology. 2008;45(5):876–882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Swerdlow  NR, Talledo JA, Braff DL. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the ‘Pacific Rim’. Psychiatr Genet. 2005;15(1):61–65. [DOI] [PubMed] [Google Scholar]
  • 58. Mendrek  A, Mancini-Marïe A. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev. 2016;67:57–78. [DOI] [PubMed] [Google Scholar]
  • 59. Abel  K, Waikar M, Pedro B, Hemsley D, Geyer M. Repeated testing of prepulse inhibition and habituation of the startle reflex: a study in healthy human controls. J Psychopharmacol. 1998;12(4):330–337. [DOI] [PubMed] [Google Scholar]
  • 60. Swanson  CL  Jr, Gur RC, Bilker W, Petty RG, Gur RE. Premorbid educational attainment in schizophrenia: association with symptoms, functioning, and neurobehavioral measures. Biol Psychiatry. 1998;44(8):739–747. [DOI] [PubMed] [Google Scholar]
  • 61. Bilder  RM, Goldman RS, Volavka J, et al.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018–1028. [DOI] [PubMed] [Google Scholar]
  • 62. Karson  C, Duffy RA, Eramo A, Nylander A-G, Offord S. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016:57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Martinez-Gras  I, Rubio G, del Manzano BA, et al.  The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone. Schizophr Res. 2009;115(2–3):215–221. [DOI] [PubMed] [Google Scholar]
  • 64. Faber  J, Fonseca LM. How sample size influences research outcomes. Dental Press J Orthod. 2014;19(4):27–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Umbricht  D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76(1):1–23. [DOI] [PubMed] [Google Scholar]
  • 66. Cadenhead  KS. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011;188(2):208–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Jeon  YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology. 2003;40(5):684–701. [DOI] [PubMed] [Google Scholar]
  • 68. Cadenhead  KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry. 2000;157(10):1660–1668. [DOI] [PubMed] [Google Scholar]
  • 69. Parwani  A, Duncan EJ, Bartlett E, et al.  Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol Psychiatry. 2000;47(7):662–669. [DOI] [PubMed] [Google Scholar]
  • 70. Braff  DL, Geyer MA, Light GA, et al.  Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001;49(1–2):171–178. [DOI] [PubMed] [Google Scholar]
  • 71. Perry  W, Minassian A, Feifel D, Braff DL. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry. 2001;50(6):418–424. [DOI] [PubMed] [Google Scholar]
  • 72. Ludewig  K, Geyer MA, Etzensberger M, Vollenweider FX. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res. 2002;55(1–2):129–137. [DOI] [PubMed] [Google Scholar]
  • 73. Mackeprang  T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry. 2002;52(9):863–873. [DOI] [PubMed] [Google Scholar]
  • 74. Ludewig  K, Vollenweider FX. Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med Wkly. 2002;132(13–14):159–165. [DOI] [PubMed] [Google Scholar]
  • 75. Ludewig  K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry. 2003;54(2):121–128. [DOI] [PubMed] [Google Scholar]
  • 76. Wynn  JK, Dawson ME, Schell AM, McGee M, Salveson D, Green MF. Prepulse facilitation and prepulse inhibition in schizophrenia patients and their unaffected siblings. Biol Psychiatry. 2004;55(5):518–523. [DOI] [PubMed] [Google Scholar]
  • 77. Perry  W, Minassian A, Feifel D. Prepulse inhibition in patients with non-psychotic major depressive disorder. J Affect Disord. 2004;81(2):179–184. [DOI] [PubMed] [Google Scholar]
  • 78. Swerdlow  NR, Light GA, Cadenhead KS, Sprock JB, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia. Arch Gen Psychiatry. 2006;63(12):1325–1335. [DOI] [PubMed] [Google Scholar]
  • 79. Minassian  A, Feifel D, Perry W. The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophr Res. 2007;89(1–3):225–231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Braff  DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007;61(10):1204–1207. [DOI] [PubMed] [Google Scholar]
  • 81. Kumari  V, Fannon D, Sumich AL, Sharma T. Startle gating in antipsychotic-naïve first episode schizophrenia patients: one ear is better than two. Psychiatry Res. 2007;151(1–2):21–28. [DOI] [PubMed] [Google Scholar]
  • 82. Kunugi  H, Tanaka M, Hori H, Hashimoto R, Saitoh O, Hironaka N. Prepulse inhibition of acoustic startle in Japanese patients with chronic schizophrenia. Neurosci Res. 2007;59(1):23–28. [DOI] [PubMed] [Google Scholar]
  • 83. Heresco-Levy  U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr Res. 2007;91(1–3):14–21. [DOI] [PubMed] [Google Scholar]
  • 84. Hong  LE, Summerfelt A, Wonodi I, Adami H, Buchanan RW, Thaker GK. Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry. 2007;164(1):61–65. [DOI] [PubMed] [Google Scholar]
  • 85. Takahashi  H, Iwase M, Ishii R, et al.  Impaired prepulse inhibition and habituation of acoustic startle response in Japanese patients with schizophrenia. Neurosci Res. 2008;62(3):187–194. [DOI] [PubMed] [Google Scholar]
  • 86. Kumari  V, Peters ER, Fannon D, et al.  Uncontrollable voices and their relationship to gating deficits in schizophrenia. Schizophr Res. 2008;101(1–3):185–194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Hong  LE, Wonodi I, Stine OC, Mitchell BD, Thaker GK. Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry. 2008;63(1):17–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Csomor  PA, Yee BK, Feldon J, Theodoridou A, Studerus E, Vollenweider FX. Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophr Bull. 2009;35(1):244–255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Moriwaki  M, Kishi T, Takahashi H, et al.  Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. Neurosci Res. 2009;65(3):259–262. [DOI] [PubMed] [Google Scholar]
  • 90. Aggernaes  B, Glenthoj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months’ treatment with quetiapine. Int J Neuropsychopharmacol. 2010;13(10):1383–1395. [DOI] [PubMed] [Google Scholar]
  • 91. Molina  V, Cortés B, Pérez J, et al.  No association between prepulse inhibition of the startle reflex and neuropsychological deficit in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2010;260(8):609–615. [DOI] [PubMed] [Google Scholar]
  • 92. Hasenkamp  W, Epstein MP, Green A, et al.  Heritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families. Psychiatry Res. 2010;178(2):236–243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Hammer  TB, Oranje B, Fagerlund B, Bro H, Glenthøj BY. Stability of prepulse inhibition and habituation of the startle reflex in schizophrenia: a 6-year follow-up study of initially antipsychotic-naive, first-episode schizophrenia patients. Int J Neuropsychopharmacol. 2011;14(7):913–925. [DOI] [PubMed] [Google Scholar]
  • 94. Hasenkamp  W, Kelley M, Egan G, et al.  Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjects. Psychiatry Res. 2011;187(3):324–328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Wang  Z, Tan Y, Yang F, et al.  The study of acoustic startle reflex in male patients with chronic schizophrenia. Asian J Psychiatr. 2012;5(1):54–57. [DOI] [PubMed] [Google Scholar]
  • 96. Light  GA, Swerdlow NR, Rissling AJ, et al.  Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012;7(7):e39434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Kishi  T, Iwata N. Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle reponses in Japanese patients with schizophrenia. Hum Psychopharmacol. 2013;28:220–229. [DOI] [PubMed] [Google Scholar]
  • 98. Ivleva  EI, Moates AF, Hamm JP, et al.  Smooth pursuit eye movement, prepulse inhibition, and auditory paired stimuli processing endophenotypes across the schizophrenia-bipolar disorder psychosis dimension. Schizophr Bull. 2014;40(3):642–652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Morales-Muñoz  I, Jurado-Barba R, Ponce G, et al.  Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res. 2014;220(1–2):535–540. [DOI] [PubMed] [Google Scholar]
  • 100. Bertelsen  B, Oranje B, Melchior L, et al.  Association study of CHRNA7 promoter variants with sensory and sensorimotor gating in schizophrenia patients and healthy controls: a Danish case–control study. NeuroMolecular Med. 2015;17( 10.1007/s12017-015-8371-9):423–430. [DOI] [PubMed] [Google Scholar]
  • 101. Shi  J, Wang Z, Tan Y, et al.  CHRNA4 was associated with prepulse inhibition of schizophrenia in Chinese: a pilot study. Cogn Neuropsychiatry. 2016;21(2):156–167. [DOI] [PubMed] [Google Scholar]
  • 102. Storozheva  ZI, Kirenskaya AV, Novototsky-Vlasov VY, Telesheva KY, Pletnikov M. Startle modification and P50 gating in schizophrenia patients and controls: Russian population. Span J Psychol. 2016;19:E8. [DOI] [PubMed] [Google Scholar]
  • 103. Matsuo  J, Ota M, Hori H, et al.  A large single ethnicity study of prepulse inhibition in schizophrenia: separate analysis by sex focusing on effect of symptoms. J Psychiatr Res. 2016;82:155–162. [DOI] [PubMed] [Google Scholar]
  • 104. Mena  A, Ruiz-Salas JC, Puentes A, Dorado I, Ruiz-Veguilla M, De la Casa LG. Reduced prepulse inhibition as a biomarker of schizophrenia. Front Behav Neurosci. 2016; 10:202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Wang  ZR, Tan YL, Yang FD, et al.  Impaired prepulse inhibition of acoustic startle in Chinese patients with first-episode, medication-naïve schizophrenia. Chin Med J (Engl). 2013;126(3):526–531. [PubMed] [Google Scholar]
  • 106. Düring  S, Glenthøj BY, Andersen GS, Oranje B. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naïve, first-episode schizophrenia patients. Neuropsychopharmacology. 2014;39(13):3000–3008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Li  XB, Bo QJ, Tian Q, et al.  Impact of childhood trauma on sensory gating in patients with first-episode schizophrenia. BMC Psychiatry. 2018;18(1):1–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Quednow  BB, Wagner M, Westheide J, et al.  Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry. 2006;59(6):536–545. [DOI] [PubMed] [Google Scholar]
  • 109. Woznica  AA, Sacco KA, George TP. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res. 2009;112(1–3):86–90. [DOI] [PubMed] [Google Scholar]
  • 110. Morales-Muñoz  I, Jurado-Barba R, Fernández-Guinea S, et al.  Sensory gating deficits in first-episode psychosis. J Nerv Ment Dis. 2016;204(12):877–884. [DOI] [PubMed] [Google Scholar]
  • 111. Swerdlow  NR. Are we studying and treating schizophrenia correctly? Schizophr Res. 2011;130(1–3):1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Heinz  A, Murray GK, Schlagenhauf F, Sterzer P, Grace AA, Waltz JA. Towards a unifying cognitive, neurophysiological, and computational neuroscience account of schizophrenia. Schizophr Bull. 2019;45(5):1092–1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Jovanovic  T, Szilagyi S, Chakravorty S, et al.  Menstrual cycle phase effects on prepulse inhibition of acoustic startle. Psychophysiology. 2004;41(3):401–406. [DOI] [PubMed] [Google Scholar]
  • 114. Green  MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry. 2001;49(4):374–384. [DOI] [PubMed] [Google Scholar]
  • 115. Weike  AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry. 2000;47(1):61–70. [DOI] [PubMed] [Google Scholar]
  • 116. Perry  W, Geyer MA, Braff DL. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry. 1999;56(3):277–281. [DOI] [PubMed] [Google Scholar]
  • 117. Perry  W, Braff DL. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry. 1994;151(3):363–367. [DOI] [PubMed] [Google Scholar]
  • 118. Meincke  U, Mörth D, Voss T, Thelen B, Geyer MA, Gouzoulis-Mayfrank E. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis—a longitudinal study. Eur Arch Psychiatry Clin Neurosci. 2004;254(6): 415–421. [DOI] [PubMed] [Google Scholar]
  • 119. Nielsen  RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185–196. [DOI] [PubMed] [Google Scholar]
  • 120. Hauser  J, Rudolph U, Keist R, Möhler H, Feldon J, Yee BK. Hippocampal alpha5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol Psychiatry. 2005;10(2):201–207. [DOI] [PubMed] [Google Scholar]
  • 121. Ioannidis  JPA. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q. 2016;94(3):485–514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Li  L, Du Y, Li N, Wu X, Wu Y. Top–down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci Biobehav Rev.2009;33(8):1157–1167. [DOI] [PubMed] [Google Scholar]
  • 123. Blumenthal  TD, Cuthbert BN, Filion DL, Hackley S, Lipp OV, van Boxtel A. Committee report: guidelines for human startle eyeblink electromyographic studies. Psychophysiology. 2005;42(1):1–15. [DOI] [PubMed] [Google Scholar]
  • 124. San-Martin  R, Zimiani MI, Noya C, et al.  A method for simultaneous evaluation of muscular and neural prepulse inhibition. Front Neurosci. 2018;12:654. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sbaa059_suppl_Supplementary_Material

Articles from Schizophrenia Bulletin are provided here courtesy of Oxford University Press

RESOURCES